

Altaf Mohammed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687980/publications.pdf>

Version: 2024-02-01

58
papers

1,757
citations

236925

25
h-index

289244

40
g-index

58
all docs

58
docs citations

58
times ranked

3033
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | DCAMKL-1 Regulates Epithelialâ€Mesenchymal Transition in Human Pancreatic Cells through a miR-200a-Dependent Mechanism. <i>Cancer Research</i> , 2011, 71, 2328-2338. | 0.9 | 192 |
| 2 | Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. <i>Translational Oncology</i> , 2013, 6, 649-657. | 3.7 | 134 |
| 3 | Sea Cucumbers Metabolites as Potent Anti-Cancer Agents. <i>Marine Drugs</i> , 2015, 13, 2909-2923. | 4.6 | 91 |
| 4 | Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 507-523. | 5.9 | 78 |
| 5 | Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48 ^{Cre/+} LSL ^{Kras} G12D/+ mice. <i>International Journal of Cancer</i> , 2012, 131, 1951-1962. | 5.1 | 67 |
| 6 | Loss of natural killer T cells promotes pancreatic cancer in LSL ^{Kras} G12D/+ mice. <i>Immunology</i> , 2017, 152, 36-51. | 4.4 | 57 |
| 7 | Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCMin/+ Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention. <i>Cancer Prevention Research</i> , 2011, 4, 2015-2026. | 1.5 | 56 |
| 8 | Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 57605-57621. | 1.8 | 55 |
| 9 | New insights into pancreatic cancer stem cells. <i>World Journal of Stem Cells</i> , 2015, 7, 547. | 2.8 | 54 |
| 10 | Î²-Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-Î± in human colon cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 181-190. | 4.1 | 52 |
| 11 | The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. <i>Cancer Prevention Research</i> , 2010, 3, 1417-1426. | 1.5 | 49 |
| 12 | Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling. <i>Cancer Prevention Research</i> , 2014, 7, 1198-1209. | 1.5 | 49 |
| 13 | Endogenous n-3 Polyunsaturated Fatty Acids Delay Progression of Pancreatic Ductal Adenocarcinoma in Fat-1-p48Cre/+LSL-KrasG12D/+ Mice. <i>Neoplasia</i> , 2012, 14, 1249-1256. | 5.3 | 46 |
| 14 | Chemopreventive Effects of Frondanol A5, a <i>Cucumaria frondosa</i> Extract, against Rat Colon Carcinogenesis and Inhibition of Human Colon Cancer Cell Growth. <i>Cancer Prevention Research</i> , 2010, 3, 82-91. | 1.5 | 44 |
| 15 | Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+LSL-KrasG12D/+ Mice. <i>Neoplasia</i> , 2012, 14, 778-785. | 5.3 | 41 |
| 16 | Molecular Pathways: Mucins and Drug Delivery in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1373-1378. | 7.0 | 40 |
| 17 | Chemopreventive Effects of RXR-Selective Retinoid Bexarotene on Intestinal Neoplasia of ApcMin/+ Mice. <i>Neoplasia</i> , 2012, 14, 159-168. | 5.3 | 39 |
| 18 | Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. <i>Oncotarget</i> , 2015, 6, 15524-15539. | 1.8 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. <i>Cancer Research</i> , 2016, 76, 1965-1974. | 0.9 | 34 |
| 20 | Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 316-324. | 0.5 | 33 |
| 21 | Prevention and treatment of cancers by immune modulating nutrients. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 1275-1294. | 3.3 | 30 |
| 22 | Molecular Targeted Intervention for Pancreatic Cancer. <i>Cancers</i> , 2015, 7, 1499-1542. | 3.7 | 30 |
| 23 | Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 33290-33305. | 1.8 | 29 |
| 24 | (Z)-3,5,4-trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. <i>Cancer Research</i> , 2016, 76, 4887-4896. | 0.9 | 28 |
| 25 | Chemoprevention of Colon and Small Intestinal Tumorigenesis in <i>APC^{min/+}</i> Mice By SHetA2 (NSC721689) without Toxicity. <i>Cancer Prevention Research</i> , 2013, 6, 908-916. | 1.5 | 27 |
| 26 | p53-stabilizing Agent CP-31398 Prevents Growth and Invasion of Urothelial Cancer of the Bladder in Transgenic UPII-SV40T Mice. <i>Neoplasia</i> , 2013, 15, 966-974. | 5.3 | 25 |
| 27 | Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer. <i>Scientific Reports</i> , 2016, 6, 37046. | 3.3 | 22 |
| 28 | Chemoprevention of Urothelial Cell Carcinoma Growth and Invasion by the Dual COX-LOX Inhibitor Licofelone in UPII-SV40T Transgenic Mice. <i>Cancer Prevention Research</i> , 2014, 7, 708-716. | 1.5 | 21 |
| 29 | Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis. <i>Cancer Prevention Research</i> , 2015, 8, 327-337. | 1.5 | 21 |
| 30 | Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice. <i>Carcinogenesis</i> , 2015, 36, 429-440. | 2.8 | 20 |
| 31 | Chemopreventive Effects of the p53-Modulating Agents CP-31398 and Prima-1 in Tobacco Carcinogen-Induced Lung Tumorigenesis in A/J Mice. <i>Neoplasia</i> , 2013, 15, 1018-1027. | 5.3 | 18 |
| 32 | Systemic Chromosome Instability Resulted in Colonic Transcriptomic Changes in Metabolic, Proliferation, and Stem Cell Regulators in <i>Sgo1^{-/-}</i> Mice. <i>Cancer Research</i> , 2016, 76, 630-642. | 0.9 | 17 |
| 33 | Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 97822-97834. | 1.8 | 16 |
| 34 | Chemopreventive Efficacy of Raloxifene, Bexarotene, and Their Combination on the Progression of Chemically Induced Colon Adenomas to Adenocarcinomas in Rats. <i>Cancer Prevention Research</i> , 2013, 6, 1251-1261. | 1.5 | 15 |
| 35 | Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein. <i>Molecular Carcinogenesis</i> , 2015, 54, 986-998. | 2.7 | 15 |
| 36 | Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer <i>In Vivo</i> . <i>Cancer Prevention Research</i> , 2016, 9, 53-62. | 1.5 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Multitargeted Low-Dose GLAD Combination Chemoprevention: A Novel and Promising Approach to Combat Colon Carcinogenesis. <i>Neoplasia</i> , 2013, 15, 481-IN5. | 5.3 | 13 |
| 38 | Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APC ^{min/+} Mouse Intestinal Tumorigenesis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 59-68. | 2.5 | 13 |
| 39 | Early and delayed intervention with Rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice. <i>Oncology Reports</i> , 2015, 34, 2925-2934. | 2.6 | 12 |
| 40 | Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). <i>Cancer Prevention Research</i> , 2021, 14, 325-336. | 1.5 | 12 |
| 41 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. <i>Cancer Prevention Research</i> , 2019, 12, 751-762. | 1.5 | 11 |
| 42 | Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic <i>Kras</i> mutation. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a. | 5.1 | 9 |
| 43 | Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells. <i>Cancer Prevention Research</i> , 2014, 7, 300-309. | 1.5 | 9 |
| 44 | Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities. <i>Toxicological Sciences</i> , 2019, 170, 251-259. | 3.1 | 9 |
| 45 | Naproxen inhibits spontaneous lung adenocarcinoma formation in <i>Kras</i> G12V mice. <i>Neoplasia</i> , 2021, 23, 574-583. | 5.3 | 9 |
| 46 | Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. <i>Oncology Reports</i> , 2013, 30, 952-960. | 2.6 | 8 |
| 47 | Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. <i>Current Medicinal Chemistry</i> , 2018, 25, 2535-2544. | 2.4 | 8 |
| 48 | Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1301-1306. | 2.3 | 7 |
| 49 | Targeting cholecystokinin ϵ 2 receptor for pancreatic cancer chemoprevention. <i>Molecular Carcinogenesis</i> , 2019, 58, 1908-1918. | 2.7 | 6 |
| 50 | Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. <i>Cancer Prevention Research</i> , 2020, 13, 273-282. | 1.5 | 6 |
| 51 | Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model. <i>Cancer Prevention Research</i> , 2020, 13, 185-194. | 1.5 | 6 |
| 52 | Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat. <i>Cancer Prevention Research</i> , 2021, 14, 1009-1020. | 1.5 | 5 |
| 53 | Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021, 26, 71-82. | 2.0 | 4 |
| 54 | Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APCMin/+ mice. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1380-1382. | 2.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Pancreatic Cancer Chemoprevention: Challenges and Opportunities. <i>Current Medicinal Chemistry</i> , 2018, 25, 2532-2534. | 2.4 | 3 |
| 56 | Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors. <i>Cancer Prevention Research</i> , 2020, 13, 897-900. | 1.5 | 3 |
| 57 | Immunoprevention of Pancreatic Cancer. <i>Current Medicinal Chemistry</i> , 2018, 25, 2576-2584. | 2.4 | 3 |
| 58 | Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. <i>Journal of Cancer Prevention</i> , 2021, 26, 309-317. | 2.0 | 1 |